Analysts: Buy Sprint Up to This Price, and 3 More Research Notes to Check Out
By Justin Lloyd-Miller | More Articles
June 19, 2013
Page 2 of 4
Vanda Pharmaceuticals (NASDAQ:VNDA): Following meetings with management, Lazard believes with increased confidence that tasimelteon will gain FDA approval, and is also more confident in the company’s outlook. The firm would use weakness to aggressively to buy shares, and reiterates its Buy rating.
NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!